Strategic report Governance & remuneration Financial statements Investor information 12 Finance expense 2015 2014 2013 m m m Interest expense arising on: financial liabilities at amortised cost 655 665 708 derivatives at fair value through profit or loss 64 23 18 Fair value hedges: fair value movements on derivatives designated as hedging instruments 10 37 fair value adjustments on hedged items 5 36 Fair value movements on other derivatives at fair value through profit or loss 6 15 2 Reclassication of cash ow hedge from other comprehensive income 2 Unwinding of discounts on provisions 16 15 14 Movements on amounts owed to non-controlling interests 2 Other finance expense 14 14 22 757 727 767 All derivatives at fair value through profit or loss other than designated and effective hedging instruments see Note 41, Financial instruments and related disclosures are classied as held-for-trading financial instruments under IAS 39.
Interest expense arising on derivatives at fair value through profit or loss relates to swap interest expense.
13 Associates and joint ventures The Groups share of after tax profits and losses of associates and joint ventures is set out below: 2015 2014 2013 m m m Share of after tax profits of associates 16 38 45 Share of after tax losses of joint ventures 2 8 2 14 30 43 At 31 December 2015, the Group held one significant associate, Theravance, Inc. now Innoviva, Inc..
This investment has been accounted for as an investment in an associate since 1 September 2015, as described in Note 20 Investments in associates and joint ventures.
Previously it was included in Other investments.
The Groups share of after tax profits of associates includes a loss of 8 million in respect of Theravance now Innoviva.
In March 2015, the Group divested half of its shareholding in Aspen Pharmacare Holdings Limited and ceased to account for the remaining investment as an associate.
The investment in Aspen is now included in Other investments Note 21.
In 2014 and 2013, Aspen was the Groups only significant associate.
Summarised income statement information in respect of Aspen is set out below for the periods in which the Group accounted for its investment in Aspen as an associate.
The Groups 2015 share of after tax profits of associates and other comprehensive income includes a profit of 10 million and other comprehensive income of 2 million in respect of Aspen.
To 20 March 2015 2014 2013 m m m Turnover 441 1,823 1,485 profit after taxation 67 313 247 Comprehensive income 16 148 192 Total comprehensive income 83 461 439 The results of Aspen included in the summarised income statement information above represent the estimated earnings of the Aspen group in the relevant periods, adjusted for transactions between GSK and Aspen.
Aggregated financial information in respect of other associated undertakings and joint ventures is set out below: 2015 2014 2013 m m m Share of turnover 188 187 225 Share of after tax profits losses 12 9 2 Share of other comprehensive income 25 Share of total comprehensive income 37 9 2 The Groups sales to associates and joint ventures were 41 million in 2015 85 million in 2014: 103 million in 2013.
The profit on disposal of interest in associates of 843 million in the year arose on the Groups divestment of one half of its shareholding in Aspen Pharmacare Holdings Limited in March 2015.
This included a gain of 457 million resulting from the change in measurement basis of the Groups retained investment in Aspen on reclassication of the investment following the divestment.
The retained investment was transferred from Investments in associates, which are equity accounted, to Other investments, which are measured at fair value.
